BRIEF published on 08/05/2024 at 11:49, 2 years 1 month ago Elmos Semiconductor SE Welcomes New Apprentices and Dual Students Elmos Semiconductor Apprenticeships Dual Students High-tech Training Dortmund
BRIEF published on 08/05/2024 at 11:49, 2 years 1 month ago Elmos Semiconductor SE accueille de nouveaux apprentis et étudiants en double Elmos Semi-conducteur Dortmund Apprentissages Étudiants Doubles Formation En Haute Technologie
BRIEF published on 08/05/2024 at 11:45, 2 years 1 month ago ATLAND : répartition du capital et des droits de vote au 31 juillet 2024 Autorité Des Marchés Financiers Droits De Vote Finances ATLAND Répartition Capital
BRIEF published on 08/05/2024 at 11:45, 2 years 1 month ago ATLAND: distribution of capital and voting rights as of July 31, 2024 Voting Rights Financial Markets Authority Finance Capital Distribution ATLAND
BRIEF published on 08/05/2024 at 11:35, 2 years 1 month ago Knorr-Bremse Aktiengesellschaft: Knorr-Bremse Sells GT Emissions Systems Knorr-Bremse Portfolio Optimization GT Emissions Systems Rcapital Partners Emission Control
BRIEF published on 08/05/2024 at 11:35, 2 years 1 month ago Knorr-Bremse Aktiengesellschaft : Knorr-Bremse vend des systèmes d'émission GT Knorr-Bremse Optimisation Du Portefeuille Systèmes D'émission GT Partenaires Rcapital Contrôle Des Émissions
BRIEF published on 08/05/2024 at 11:29, 2 years 1 month ago Déclaration mensuelle des droits de vote au 31 juillet 2024 par HighCo Droits De Vote Actions Investisseurs Réglementation AMF HighCo
BRIEF published on 08/05/2024 at 11:29, 2 years 1 month ago Monthly declaration of voting rights as of July 31, 2024 by HighCo Voting Rights Investors Actions AMF Regulations HighCo
BRIEF published on 08/05/2024 at 10:37, 2 years 1 month ago Medios Expands Advanced Therapies and Appoints Dr. Andreas Schmiede as VP Medios AG Advanced Therapies Personalized Medicine Specialty Pharma Dr. Andreas Schmiede
BRIEF published on 08/05/2024 at 10:37, 2 years 1 month ago Medios étend ses thérapies avancées et nomme le Dr Andreas Schmiede au poste de vice-président Medios AG Médecine Personnalisée Pharmacie Spécialisée Thérapies Avancées Dr Andreas Schmiede
Published on 09/11/2026 at 04:00, 8 hours 43 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 14 hours 18 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 21 hours 23 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 21 hours 43 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 11:43, 1 hour ago Skyborn reaches Financial Close on the Gennaker offshore wind farm project
Published on 09/11/2026 at 11:35, 1 hour 7 minutes ago EQS-Adhoc: Correction of a release from 10/09/2026, 19:35 CET/CEST - United Internet AG: Group subsidiaries 1&1 AG and IONOS Group SE launch transformation programs
Published on 09/11/2026 at 11:30, 1 hour 13 minutes ago Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Published on 09/11/2026 at 10:15, 2 hours 28 minutes ago TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 07:00, 5 hours 43 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 5 hours 43 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 5 hours 43 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 17 hours 13 minutes ago Availability of the 2026 Interim Financial Report
